Qiming U.S. Ventures Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Qiming U.S. Ventures Management, LLC reported 6 stock positions worth $89.7 million. Its top holding was Korro Bio (KRRO) at 36.9% of the portfolio, followed by Jasper Therapeutics (JSPR, 30.4%) and Tourmaline Bio (TRML, 18.9%). Compared with Q4 2023, it opened 1 new position, sold out of 3, added to 1 and reduced 1. The biggest buy was a new position in Jasper Therapeutics (JSPR) and the biggest sale an exit from Icosavax (ICVX).
- Most Recent 13F
- Q3 2025
- Location
- BELLEVUE, WA
- CIK
- 0001909617
- Portfolio Value
- $89.7M (Q1 2024)
- SEC Filing
- 0001104659-24-061168 ↗ filed May 14, 2024
Holdings Value
Holdings 6 stocks · $89.7M
| KRRO Korro Bio Inc. | 36.93% | 368,085 | $33.1M | No change |
| JSPR Jasper Therapeutics Inc. | 30.41% | 928,964 | $27.3M | New |
| TRML Tourmaline Bio Inc. | 18.94% | 741,691 | $17.0M | Add +15.6% |
| HLVX Hillevax Inc. | 10.36% | 558,923 | $9.3M | No change |
| VTYX Ventyx Biosciences Inc. | 2.53% | 412,225 | $2.3M | Reduce -39.9% |
| KEZAR LIFE SCIENCES INC | 0.83% | 828,711 | $747K | No change |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 4 | $55.6M | TRML, KRRO, JSPR, KZR |
| Q2 2025 | 6 | $23.6M | TRML, JSPR, KRRO, VTYX, HLVX |
| Q1 2025 | 6 | $23.1M | TRML, KRRO, JSPR, HLVX, VTYX |
| Q4 2024 | 6 | $51.1M | JSPR, TRML, KRRO, VTYX, HLVX |
| Q3 2024 | 6 | $51.4M | TRML, JSPR, KRRO, HLVX, VTYX |
| Q2 2024 | 6 | $52.6M | JSPR, KRRO, TRML, HLVX, VTYX |
| Q1 2024 | 6 | $89.7M | KRRO, JSPR, TRML, HLVX, VTYX |